Business ❯ Pharmaceuticals

Biotechnology

Drug Development Clinical Trials Acquisitions Clinical Development Cancer Treatment Mergers and Acquisitions Partnerships Gene Editing Vaccine Development Research and Development

BioMarin and Ascendis Reach Global Patent Settlement Over Yuviwel

The deal creates a time‑limited royalty stream to BioMarin through May 2030 and removes the threat of an ITC import enforcement action.

BioNTech Terminates Phase 2 Colorectal Trial of Autogene Cevumeran as Shares Drop

FDA Approves Regeneron’s Pasatru for Adults With FOP

FDA Panel Rejects Deramiocel Cardiac Claim After Lancet Publishes HOPE‑3 Results

Lilly Expands Neuroscience Pipeline With $2.8 Billion Purchase of AtaiBeckley

FDA Staff Flags Major Flaws in Capricor’s Deramiocel Data

argenx Posts $1.52 Billion Quarter as VYVGART Readouts Loom

Novartis to Acquire Myricx Bio for Up to $1.5 Billion

Viking Therapeutics Rallies as Weight‑Loss Program Moves Toward Late‑Stage Testing

AbbVie Agrees to Buy Apogee Therapeutics for $10.9 Billion

Eli Lilly Licenses AlzeCure’s Preclinical Alzheimer’s Candidate

Alnylam and Inceptive Agree Up to $2 Billion Partnership to Use AI for siRNA Drug Design

Grifols Starts Building 80,000 m² Plasma Complex in Lliçà de Vall

Lilly Wins Exclusive License to Ascidian RNA Exon-Editing Platform for Kidney Diseases

Multiple Firms Compete to Lead Medpace Securities Suit After Lower Book‑to‑Bill Disclosure

Pfizer and Innovent Strike Up to $10.5 Billion Oncology Collaboration

One Infusion Cuts LDL by Up to 62% in Early Gene‑Editing Trial

Regeneron to Open Global Capability Centre in Hyderabad

Regeneron Strikes Parabilis Deal to Develop Antibody-Helicon Drugs

FDA Clears Vepdegestrant, First PROTAC Cancer Drug, for ESR1‑Mutated Breast Cancer